In a similar way, the PPARγ Q286E mutation in our study elicited transactivation regardless of ligand binding, thus supporting the pro-tumorigenic effects of PPARγ gain-of-function mutations in bladder cancer. This evidence concerns the gene PPARG and urinary bladder cancer.